|Emitents||Grindeks, AS (5299006DWR32NKWM1O86)|
|Veids||2.2. Iekšējā informācija|
In response to the request by Nasdaq Riga to prepare and submit additional information on remuneration of the Supervisory Council of JSC “Grindeks” Group, we hereby inform that Supervisory Council of JSC “Grindeks” was re-elected at the Annual General Meeting of shareholders of JSC “Grindeks” held on 7 June 2016. At the meeting shareholders who were informed about the draft resolution on remuneration of the Supervisory Council at the time did approve it with their vote applying it to full term of office.
There has been Group’s Supervisory Council’s remuneration increase as JSC “Grindeks” Group’s results of operations have dynamically improved since 2016.
“Grindeks” is an international pharmaceutical company focused on research, development, manufacturing and sales of original products, generics and active pharmaceutical ingredients. The Group of “Grindeks” has five subsidiary companies in Latvia, Estonia, Russia and Slovakia as well as representative offices in 12 countries.
“Grindeks” specializes in the heart and cardiovascular, CNS, anti-cancer and gastroenterological medication therapeutic groups. A range of products covers a combination of original products Mildronate® (meldonium*) and Ftorafur®, generics, food supplements and active pharmaceutical ingredients.
In 2017 products of the company were exported to 77 countries with export comprising 92.5% of the total turnover. The key markets include the EU countries, Russia and the other CIS countries, the U.S., Canada, Japan and Vietnam.
To increase production capacity and develop infrastructure, the company has accomplished many significant investment projects, investing around 100 million euros over the last 15 years.
*Notice: meldonium is included in the list of substances prohibited in sport.